Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2020 Dec 8;20(2):274–283. doi: 10.1158/1535-7163.MCT-20-0567

Figure 1. Leflunomide induced apoptosis and tumor regression in HeLa cells.

Figure 1.

(A). SRB analysis of leflunomide dose-response in HeLa cells from Day 3 to 6. (B) HeLa cells were treated with the indicated concentration of leflunomide for 24 hrs, and cell lysates were analyzed using indicated antibodies. (C) Annexin-V/7AAD flow cytometry analysis of HeLa cells treated with 0 or 100 μM of leflunomide for 72 hrs. (D) HeLa xenograft growth over the 21-day treatment period (X-axis). Y-axis represents Ln(Tumor Volume in mm3). (E) A rolling enrollment was used for the treatment of HeLa xenografts, and treatment was initiated on day 6 (left), 9 (middle), and 15 (right) after tumor implantation. All mice were treated with vehicle or leflunomide for 21 days. Top panels are photos of nude mice bearing subcutaneous HeLa xenografts 21 days after treatment. The bottom panel is the comparison of isolated HeLa xenografts. (F) Tumor Weight (in grams) comparison in the control and treated group with indicated Kruskal-Wallis p-value.